Class C CpG oligodeoxynucleotides as a single agent and in combination with radiotherapy efficiently delayed growth of subcutaneous B16F1 tumors

被引:6
作者
Cerkovnik, Petra [1 ]
Novakovic, Barbara Jezersek [2 ]
Stegel, Vida [1 ]
Novakovic, Srdjan [1 ]
机构
[1] Inst Oncol Ljubljana, Dept Mol Diagnost, Ljubljana 1000, Slovenia
[2] Inst Oncol Ljubljana, Div Med Oncol, Ljubljana 1000, Slovenia
关键词
CpG ODN; dendritic cells; innate immunity; radiotherapy; tumor vaccine; MURINE TUMORS; ANTITUMOR IMMUNITY; DENDRITIC CELLS; MELANOMA MODEL; VACCINE; ACTIVATION; THERAPY; GENE; ODN; OLIGONUCLEOTIDES;
D O I
10.1177/1753425909105581
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Until now, the anti-tumor efficacy of synthetic oligodeoxynucleotides containing CpG motifs (CpG ODNs) has been reported in a number of preventive and therapeutic tumor models. Predominately class B CpG ODNs were used, relatively little has been reported regarding the class C CpG ODNs. The present study was, therefore, aimed at assessing the ability of CpG ODNs class C applied as a single agent and in combination with radiotherapy to induce the anti-tumor immunity in an experimental tumor model in mice (subcutaneous [s.c.] B16F1). Class C CpG ODNs applied three times as a single agent efficiently delayed the growth of s.c. B16F1 tumors. The combined therapy (CpG ODNs and tumor irradiation) remarkably enhanced the anti-tumor effect. The peritumoral (p.t.) application of CpG ODNs in combination with irradiation increased the number of dendritic cells (DCs) at the tumor site and improved the antigen loading and maturation of DCs. In conclusion, the combined therapy with CpG ODNs and irradiation creates a unique in situ DCs vaccine that could be easily applicable without prior knowledge of tumor antigens.
引用
收藏
页码:313 / 321
页数:9
相关论文
共 31 条
  • [1] Interferon α and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects
    Brown, Lloyd
    Roda, Julie
    Terrell, Catherine
    Chaudhury, Abhik Ray
    Crespin, Tim
    Carson, William E.
    Lesinski, Gregory B.
    [J]. SURGERY, 2006, 140 (02) : 297 - 306
  • [2] Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides
    Buhtoiarov, Ilia N.
    Sondel, Paul M.
    Eickhoff, Jens C.
    Rakhmilevich, Alexander L.
    [J]. IMMUNOLOGY, 2007, 120 (03) : 412 - 423
  • [3] Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?
    Bui, Jack D.
    Schreiber, Robert D.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2007, 19 (02) : 203 - 208
  • [4] Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
    Carpentier, A
    Laigle-Donadey, F
    Zohar, S
    Capelle, L
    Behin, A
    Tibi, A
    Martin-Duverneuil, N
    Sanson, M
    Lacomblez, L
    Taillibert, S
    Puybasset, L
    Van Effenterre, R
    Delattre, JY
    Carpentier, AF
    [J]. NEURO-ONCOLOGY, 2006, 8 (01) : 60 - 66
  • [5] Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity
    Davila, E
    Celis, E
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (01) : 539 - 547
  • [6] Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine
    den Brok, Martijn H. M. G. M.
    Sutmuller, Roger P. M.
    Nierkens, Stefan
    Bennink, Erik J.
    Toonen, Liza W. J.
    Figdor, Carl G.
    Ruers, Theo J. M.
    Adema, Gosse J.
    [J]. CANCER RESEARCH, 2006, 66 (14) : 7285 - 7292
  • [7] Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma:: increased interferon-α/β-inducible gene expression, without significant toxicity
    Friedberg, JW
    Kim, H
    McCauley, M
    Hessel, EM
    Sims, P
    Fisher, DC
    Nadler, LM
    Coffman, RL
    Freedman, AS
    [J]. BLOOD, 2005, 105 (02) : 489 - 495
  • [8] Induction of potent antitumor immunity by in situ targeting of intraturnoral DCs
    Furumoto, K
    Soares, L
    Engleman, EG
    Merad, M
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (05) : 774 - 783
  • [9] Heckelsmiller K, 2002, EUR J IMMUNOL, V32, P3235, DOI 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO
  • [10] 2-J